These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33674928)

  • 1. Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
    Ma X; Bellomo L; Magee K; Bennette CS; Tymejczyk O; Samant M; Tucker M; Nussbaum N; Bowser BE; Kraut JS; Bourla AB
    Adv Ther; 2021 Apr; 38(4):1843-1859. PubMed ID: 33674928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
    Griffith SD; Tucker M; Bowser B; Calkins G; Chang CJ; Guardino E; Khozin S; Kraut J; You P; Schrag D; Miksad RA
    Adv Ther; 2019 Aug; 36(8):2122-2136. PubMed ID: 31140124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
    Torres AZ; Nussbaum NC; Parrinello CM; Bourla AB; Bowser BE; Wagner S; Tabano DC; George D; Miksad RA
    Adv Ther; 2022 Jun; 39(6):2831-2849. PubMed ID: 35430670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.
    Ma X; Bellomo L; Hooley I; Williams T; Samant M; Tan K; Segal B; Bourla AB
    JAMA Netw Open; 2022 May; 5(5):e229655. PubMed ID: 35552726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
    Griffith SD; Miksad RA; Calkins G; You P; Lipitz NG; Bourla AB; Williams E; George DJ; Schrag D; Khozin S; Capra WB; Taylor MD; Abernethy AP
    JCO Clin Cancer Inform; 2019 Aug; 3():1-13. PubMed ID: 31403818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
    Lu Y; Langerman SS; McCain E; Magee K; Maund SL; Srivastava MK; Samant M
    JAMA Netw Open; 2024 May; 7(5):e249286. PubMed ID: 38700864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer.
    Izano MA; Tran N; Fu A; Toland L; Idryo D; Hilbelink R; Tu H; Hsu H; Sommers C; Rioth M; Brown T
    Clin Lung Cancer; 2022 May; 23(3):191-194. PubMed ID: 35283071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy.
    McKelvey BA; Garrett-Mayer E; Rivera DR; Alabaster A; Andrews HS; Bond EG; Brown TD; Bruno A; Damato L; Espirito JL; Fernandes LL; Hansen E; Kluetz P; Ma X; McCracken A; Mishra-Kalyani PS; Natanzon Y; Potter D; Robert NJ; Schwartz L; Schwind R; Sweetnam C; Wagner J; Stewart MD; Allen JD
    JCO Clin Cancer Inform; 2024 Aug; 8():e2400091. PubMed ID: 39146509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
    Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
    Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
    Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
    Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.
    Arbour KC; Luu AT; Luo J; Rizvi H; Plodkowski AJ; Sakhi M; Huang KB; Digumarthy SR; Ginsberg MS; Girshman J; Kris MG; Riely GJ; Yala A; Gainor JF; Barzilay R; Hellmann MD
    Cancer Discov; 2021 Jan; 11(1):59-67. PubMed ID: 32958579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential frequency in imaging-based outcome measurement: Bias in real-world oncology comparative-effectiveness studies.
    Adamson BJS; Ma X; Griffith SD; Sweeney EM; Sarkar S; Bourla AB
    Pharmacoepidemiol Drug Saf; 2022 Jan; 31(1):46-54. PubMed ID: 34227170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.